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Introduction: The incidence rate of lung adenocarcinoma
(LUAD), the predominant histological subtype of lung can-
cer, is elevated in Asians, particularly in female nonsmokers.
The mutation patterns in LUAD in Asians might be distinct
from those in LUAD in whites.
Methods: We proﬁled 271 resected LUAD tumors (mainly
stage I) to characterize the genomic landscape of LUAD in
Asians with a focus on female nonsmokers.
Results: Mutations in EGFR, KRAS, erb-b2 receptor tyrosine
kinase 2 gene (ERBB2), and BRAF; gene fusions involving
anaplastic lymphoma receptor tyrosine kinase gene (ALK),
ROS1, and ret proto-oncogene (RET); and Met Proto-
Oncogene Tyrosine Kinase (MET) exon 14 skipping were
the major drivers in LUAD in Asians, exhibiting mutually
exclusive and differing prevalence from those reported in
studies of LUAD in non-Asians. In addition, we identiﬁed a
novel mutational signature of XNX (the mutated base N in
the middle ﬂanked by two identical bases at the 50 and 30
positions) that was overrepresented in LUAD tumors in
nonsmokers and negatively correlated with the overall
mutational frequency.
Conclusions: In this cohort, approximately 85% of in-
dividuals have known driver mutations (EGFR 59.4%, KRAS7.4%, ALK 7.4%, ERBB2 2.6%, ROS1 2.2%, RET 2.2%, MET
1.8%, BRAF 1.1%, and NRAS 0.4%). Seventy percent of
smokers and 90% of nonsmokers had deﬁned oncogenic
drivers matching the U.S. Food and Drug Administration–
approved targeted therapies.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Lung cancer is one of the most complex and hetero-
geneous malignancies, both in phenotypic and molecular
terms. Thus, despite recent advances in targeted cancer
therapies, lung cancer remains the leading cause of
cancer-related death worldwide. Although tobacco
smoking is the primary cause of lung cancer for all his-
tological subtypes, it is most strongly associated with
squamous cell carcinoma and SCLC.1 Nevertheless, lung
cancer does occur in people who have never smoked or
had prolonged exposure to second-hand smoke. In fact,
with the decline of lung cancer cases attributable to to-
bacco smoking, the relative prevalence of lung adeno-
carcinoma (LUAD), a subtype of lung cancer inﬂicting
smokers and nonsmokers alike, has risen sharply in
recent years.2
Indeed, LUAD is the most frequent type of lung can-
cer in nonsmokers, occurring more frequently in females
than in males.3 Previous genomics studies of LUAD in
whites have identiﬁed common driver gene mutations
the prevalence of which varies between smokers and
nonsmokers. Speciﬁcally, KRAS mutations are observed
in 35% of smokers but occur much less frequently in
nonsmokers.4 Conversely, EGFR mutations occur more
often in nonsmokers. In contrast, KRAS mutations are
rare in LUAD in Asians,5,6 whereas EGFR mutations have
a prevalence of up to 68% and are the predominant
driver gene mutations. In addition to mutations, gene
fusion events in lung cancer have gained recognition
since the initial report of anaplastic lymphoma receptor
tyrosine kinase gene (ALK) rearrangements in 2007. In
subsequent years, other ALK fusion events were found in
other types of cancer.7 Although the prevalence of ALK
fusions in LUAD is approximately 3% to 5%, such fu-
sions were found to be enriched in a cohort of female
nonsmokers.8 After the clinical success of targeted
treatment in patients with ALK fusion–positive tumors,
other oncogenic fusion events involving ROS1 and RET
were reported. As in the case of ALK fusions, ROS1 and
ret proto-oncogene (RET) rearrangements have a low
incidence in LUAD, occurring in approximately 1% of all
cases.9 It was also found that the rearrangements of ALK,
ROS1, and RET are mutually exclusive with major driver
gene mutations such as KRAS and EGFR oncogenic mu-
tations. Together, these genomic events constitute the
top-ranked known drivers of LUAD tumorigenesis,8,10–12
leaving additional genetic causes yet to be identiﬁed in
almost 25% of LUAD cases.
Several genomics studies of NSCLC involving whites
and smokers have been published,13–16 but the genome
characterization of lung cancer17,18 in Asian patients is
limited. Considering that different response rates to
molecularly targeted treatment modalities occur amongdifferent ethnic groups,19 one of the most pressing needs
to leverage genome-based medicine in LUAD in Asians is
to characterize the associated oncogenic driver gene
mutations and identify actionable mutations. Here the
Asian Cancer Research Group reports on the genomics
landscape of LUAD in Asian patients, following the
genomic characterization of hepatocellular carcinoma
and gastric cancer in Asians.20,21
The high frequency and predominance of known driver
gene mutations in LUAD, as revealed by cancer genome
sequencing results deposited in The Cancer Genome Atlas
(TCGA), have hindered the identiﬁcation of novel driver
gene mutations in genome sequencing endeavours. To
overcome the challenge of redundantly identifying the
most frequent known driver mutations, we adopted a
hybrid approach combining low-cost direct screening for
known oncogenic driver mutations and whole-genome
sequencing (WGS) for discovery of novel mutations.
We ﬁrst screened 271 LUAD tumor samples (86
smokers and 185 nonsmokers) for driver gene alterations
in the ﬁve most frequently mutated genes, namely, EGFR,
KRAS, ALK, ROS1, and RET. Only 62 (22.9%) of the 271 tu-
mor samples were negative for any of these gene alter-
ations.Matching tumor and adjacent normal tissue samples
were selected from 33 LUAD cases self-reported in non-
smokers and subjected to WGS and characterization.
Taking together, the data presented in this study
provide a comprehensive characterization of the
genomic landscapes of LUAD in Asian patients and may
serve as a reference for the path to personalized medi-
cine for Asian patients with LUAD.
Materials and Methods
Patient Material
A total of 271 fresh frozen tissue samples and
matched adjacent normal tissue samples were surgically
resected at the Samsung Medical Center from 2007 to
2012, with prior informed consent from patients and
approval from the institutional review board.
EGFR/KRAS Mutation Screening by MassARRAY
The iPLEX MassARRAY System (Sequenom, Inc., San
Diego, CA) was used to screen for 34 EGFR and 10 KRAS
known oncogenic mutations (Supplementary Table 1).
MassARRAY Assay Design Software 4.0 was used to
design the polymerase chain reaction (PCR) and
MassEXTEND primers. Reactions were automatically
spotted to a 384 SpectroCHIP with a MassARRAY
Nanodispenser RS1000 (Sequenom). MassARRAY
needed 10 ng of DNA to detect EGFR/KRAS mutations.
The performance of each assay within each sample was
manually conﬁrmed by examining the spectra with
MassARRAY Typer 4.0 software (Sequenom).
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Skipping Screening by NanoString Assay
A NanoString-based assay was used to determine the
presence or absence of ALK, ROS1, and RET fusion
transcripts.22 A hybridization probe spanning MNNG
Met Proto-Oncogene Tyrosine Kinase (MET) exons 13
and 14 was also incorporated into the assay to detect
transcripts resulting from exon 14 skipping in the
MET gene.Library Preparation and WGS
DNA was extracted from fresh frozen tumor and
matched adjacent normal tissue samples using QIAamp
DNA Mini Kit (Qiagen, Valencia, CA). All the tumor
specimens had a tumor cell content of 70% to
approximately 95%. In ﬁve cases in which matched
normal tissue samples were unavailable, matched
blood was used as the normal control. A quantity of 5
mg of high-quality genomic DNA from each sample
was sheared into approximately 500–base pair (bp)
fragments and used to construct three paired-end
libraries. Each sample was sequenced by using an
Illumina HiSeq 2000 instrument (Illumina, San Diego,
CA) with 100-bp reads.Table 1. Clinical Features of Selected Patients
Clinical Features (N ¼ 271) Value
Median age at surgery (range), y 59 (21–82)
Sex n
Male 118
Female 153
Smoking Status
Smoker 86
Nonsmoker 185
Female nonsmoker 147
Male nonsmoker 38
Tumor stage
I 174
II 41
III 48
IV 8
Recurrence status
Yes 69
No 186
NA 16
Survival
Median d to PFS (range) 895 (51–2043)
Median days to death (range) 1022 (51–2064)
PFS, progression-free survival.Mapping to a Human Reference Genome and
Variant Calling
For WGS data, after low-quality reads were removed,
the clean sequencing data were aligned to a human
reference genome (hg19) by using the Burrows-Wheeler
Aligner.23 We used an in-house–developed software
named SOAPsnv24 to predict somatic point mutations.20
The performance of the software in predicting somatic
point mutations was validated by PCR and Sanger
sequencing in the previous study. The somatic indel
calling pipeline20 was based on the split-read identiﬁ-
cation, calibrated method.25
We used SegSeq26 to infer somatic copy number
variations in LUAD samples and the corresponding
normal samples. We then implemented the Genomic
Identiﬁcation of Signiﬁcant Targets in Cancer algo-
rithm27 to discern recurrent ampliﬁcation and deletion
regions, using 10-kb windows instead of single-
nucleotide polymorphism array probes.
The clipping reveals structure (CREST) algorithm28
was used to detect somatic structure variations (SVs).
After generating prediction results, we merged the
SVs containing the nearest breakpoints (<10 bp),
which might be caused by microhomologous sequences.
Then, we used the CREST algorithm to reanalyze for
germline SVs on the basis of normal samples, and
all normal samples were combined to ﬁlter out the
germline SVs.Using NMF to Characterize Genome Features
Nonnegative matrix factorization (NMF) has been
frequently used to characterize mutational-spectrum
signatures on the basis of single-nucleotide variation
(SNV) results. A detailed description of NMF method can
be found in previous study.29 Through this method, four
mutational signatures were identiﬁed by evaluating the
cophenetic correlation and sparseness (Supplementary
Fig. 1A).Results
Genome Landscape of LUAD
Initially, this study was focused on cases involving
Asian nonsmokers. In total, 185 nonsmoking patients
with LUAD were selected for this study from the Sam-
sung Medical Centre; 82.75% of them were female
owing to sex-based differences in smoking habits in
Asia. We then randomly selected 86 cases involving a
smoker as an expanded cohort, of which only 7% of
were female. The median age of the 271 patients with
LUAD was 59 years (range 21–82), which is similar to
that in a previous study of an Asian population13,16
(Table 1). Additional patient demographics are
described at Supplementary Table 2.
Because known oncogenic drivers (KRAS, EGFR, ALK,
ROS1, and RET) were expected to occur in most LUAD
cases, we initially screened the 271 LUAD tumors for the
presence of the ﬁve oncogenes to maximize the proba-
bility of discovering novel unknown drivers. A direct
hybridization method using NanoString technology was
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Overall, 32 of 271 tumors were positive for these gene
fusions, with 20 gene fusions occurring in ALK and six
gene fusions occurring in either ROS1 or RET. EGFR and
KRAS mutations were screened by using the Sequenom
MassARRAY method, and the results are shown in
Supplementary Table 1. In summary, 157 tumors with
EGFR mutations and 20 tumors with KRAS mutations
were identiﬁed. All mutations in the ﬁve genes were
found to be mutually exclusive in this study. The
remaining 62 samples in our LUAD cohort had no known
mutations in these ﬁve oncogenes.
We selected 33 self-reported nonsmoker patients
with LUAD from the quintuple-negative group with suf-
ﬁcient amounts of both tumor and matched normal
DNAs for WGS to identify potential unknown driver
mutations (Supplementary Table 3 and Supplementary
Fig. 2). Both tumor and normal tissue samples or blood
from these 33 patients were analyzed by WGS using an
Illumina HiSeq 2000 instrument (Illumina), and at least
99% of the genome in each case was covered with more
than 10 redundancy. After acquiring the high-quality
sequencing data, we used SOAPsnv20 and split-read
identiﬁcation, calibrated25 to identify somatic SNVs and
indels in the paired genomes. Overall, we detected
approximately 130,000 SNVs and approximately 69,000
indels from the 33 tumor samples. Among these muta-
tions, 789 were nonsilent SNVs and 97 indels were
mutated in the coding sequence (CDS) region
(Supplementary Tables 4 and 5). Overall, the average
mutation rate reached 1.38 SNVs per megabase, which is
in agreement with previous studies.16,30 Mutations rates
in each sample ranged from 0.16 to 12.4 SNV per Mb
(see Supplementary Table 4), and several samples were
found to have outlier mutation ratios. After comparing
their SNV mutational spectra and mutation ratios
(Fig. 1A) with previous data from cases involving pa-
tients with lung cancer who were smokers,13,15,31 we
identiﬁed four cases in which the mutational features in
smokers were comparable to those found in self-
reported nonsmokers. In follow-up consultations, two
patients (124T and 154T) were subsequently found to
have a history of previous smoking, although the other
two patients (132T and 274T) could not be contacted.
We thus deﬁned these four cases as smoking patients for
the purpose of subsequent analysis.
To further characterize the genomic proﬁles of the
patients with LUAD, we analyzed the observed SNV
mutational statuses in terms of somatic substitutions in
an adjacent, trinucleotide context. SNVs and ﬂanking 50
and 30 bases were visualized by heatmap analysis
(Supplementary Fig. 1B). We used NMF to examine
mutational signatures beyond the mutational spec-
trum.29 Evaluation of NMF decompositions29 suggestedthat an estimated four biologically distinct mutational
signatures were present in the 33 cancers (designated
A–D [Supplementary Fig. 2]). Consistently, signature C,
which had a prominent C>A transversion, was identiﬁed
as the major component in the four cases involving
smokers (124T, 154T, 132T, and 274T), which is in
agreement with several previous studies.13,15,29,31 Most
interestingly, signature A (also referred to as the XNX
signature because of the presence of same base at the
ﬂanking 50 and 30 positions relative to the mutated base
N) was a novel ﬁnding in nonsmokers (Fig. 1B) that had
not been seen in the previously published cancer
genome sequencing studies. The abundance of the XNX
signature was negatively correlated with SNV occurrence
(Fig. 1C). Thus, tumors with a higher prevalence of the
XNX signature contained lower mutation ratios in the
CDS regions (including splicing sites) in nonsmokers
(Fig. 1D), indicating that this signature may represent a
background mutation process. We hypothesize that the
occurrence of identical 50 and 30 bases relative to a
mutation site may stabilize the local DNA structure,
thereby making it more difﬁcult for cells to repair DNA
mutations during replication, relative to other mutations.
As tumors develop, DNA repair pathways can be easily
impaired by mutations. Consequently, most mutations
are accumulated, which makes the XNX signature difﬁ-
cult to discern. Thus, the XNX signature may potentially
be used to measure genome stability. Patients with
higher XNX signature ratios showed a tendency to have
their disease diagnosed in stage I and to be younger
patients, but these differences were not statistically
signiﬁcant for the limited set of patient samples studied
here.
Besides the C>A signature observed in smokers and
the XNX signature observed in nonsmokers, we found
only one LUAD tumor with a kataegis signature32
(signature D), which was observed as a small hyper-
mutated region in chromosome 7 containing numerous
clusters of C >T and C>G mutations (Supplementary
Fig. 3). Signature B was mainly characterized by
X(C>T)G mutations in non-CpG island regions, which
have been detected in several cancers.29
Somatic copy number alterations (CNAs) were
examined using published methods13,26 (Supplementary
Fig. 4). Focal somatic CNA events at 1q, 5p, 6p, 7p, 8q
16q, 17q, 20p, and 20q were recurrent in this cohort,
which is in agreement with previous ﬁndings.15,29 The
highest G-score of ampliﬁcation occurred at 12q15,
which included signiﬁcant ampliﬁcation of the mdm1
nuclear protein gene (MDM1) with an adjusted p value
less than 0.0001. The most signiﬁcant deletion region
events occurred at 19p13.2 and 13q34, which included
the tyrosine kinase 2 gene (TYK2) and insulin receptor
substrate 2 gene (IRS2) genes with an adjusted p value
Figure 1. Summary of genetic alterations in 33 lung adenocarcinoma tumors. (A) Histograms showing the number or extent of
alterations found for each genetic parameter across different subgroups. Tumors were grouped by molecular subtype with a
blue dotted line (see Supplementary Fig. 1B) and sorted in descending order according to the number of somatic single
nucleotide variations (SNVs) within each group. Starting from the top, the panels show (for each patient) the SNV number, the
driver gene, the signature component ratio (used to classify tumors into different groups), and the mutation spectrum. (B)
Relative contribution of each mutation type to each of four mutational signatures, as identiﬁed by nonnegative matrix
factorization analysis (see Methods section). (C and D) Scatter plot with linear ﬁtting between the tumors’ component ratios
of signature A to the log2 total SNV mutational number (C) or the ratio of the number of SNVs mutated in the coding sequence
(CDS) to the total number of SNVs (D). ERBB2, erb-b2 receptor tyrosine kinase 2 gene; MET, Met proto-oncogene tyrosine
kinase.
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Supplementary Table 6).
A total of 2642 somatic SVs were detected among the
33 tumors by using CREST software.28 The SV events in
each patient ranged from three to 357 After these SVs
were annotated, no signiﬁcant SV events involving
typical oncogenic rearrangements were found in the 33
tumors. The recently discovered gene fusions involving
the neurotrophic tyrosine receptor kinase family33 were
not observed in this cohort.
Oncogenic Drivers in Samples of Asian
Nonsmokers with LUAD
On the basis of the SNV/indel ﬁndings, we used the
method described by Youn and Simon34 to predict
signiﬁcantly mutated genes.20 Genes with adjusted p
values less than 0.05 were considered signiﬁcantly
mutated (summarized in Supplementary Table 7). In
total, 13 genes were predicted as signiﬁcantly mutatedFigure 2. Distribution of mutations in cancer genes predicted
represent those that were present in more than one sample.
parentheses. (B) Amino acid sequence near the erb-b2 recepto
Met proto-oncogene tyrosine kinase; SETD2, SET domain contagenes, including two tumor suppressor genes (tumor
protein p53 gene [TP53] and SET domain containing 2
gene [SETD2]) and three oncogenes (EGFR, erb-b2 re-
ceptor tyrosine kinase 2 gene [ERBB2], and MET).
Six LUAD tumors with ERBB2 insertions were iden-
tiﬁed. A p.A775_G776insYVMA mutation occurred in ﬁve
patients, and an adjacent insertion (p.V777_G778insG)
mutation occurred in another patient (Fig. 2A). ERBB2
insertions were previously found in LUAD,35 and our
results indicated an important role for this mutation in
Asian nonsmokers with LUAD.
We also identiﬁed insertions in the kinase domain of
the EGFR gene (Fig. 2A). Closer inspection of
p.A775_G776insYVMA in ERBB2 and p.A767_S768insSVD
in EGFR revealed that they had the same type of tandem
duplication and shared the same upstream sequences
(coding for TSPKANKEILDEA), as shown in Figure 2B.
All these insertions were validated by PCR and
Sanger sequencing (Supplementary Fig. 5). As previouslyby whole-genome sequencing. (A) Mutations shown in red
The number of samples with each mutation is indicated in
r tyrosine kinase 2 gene (ERBB2)/EGFR insertion sites. MET,
ining 2 gene; TP53, tumor protein p53 gene.
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younger patients36 (see Supplementary Fig. 5B). These
insertions could potentially promote EGFR activation
through a different mechanism than EGFR-sensitizing
mutations (mainly L858R and exon 19 deletions), which
increase the afﬁnity of EGFR for inhibitors. The degree of
inhibition observed was similar to that seen in EGFR
proteins with the resistant mutation Thr790Met.37,38
However, as previously reported,39 EGFR and ERBB2
exon 20 insertions depend on heat shock protein 90
(Hsp90) for stability and downstream signaling
capability and are highly sensitive to Hsp90 inhibition.
Thus, Hsp90 inhibitors might be considered for treating
LUADs harboring exon 20 insertions in either EGFR
or ERBB2.Figure 3. Landscape of oncogenes in tumor samples from As
signiﬁcantly mutated oncogenes found in 229 LUAD tumors. The
prescreening step, and the right panel shows samples detecte
indicates samples showing MET exon 14 skipping, as well as a
harbor known oncogenes are not represented in (A). The mutati
for NRAS because of its extremely low frequency (one of 271)
oncogenes was detected, but no recurrent erb-b2 receptor tyro
were screened for in the samples. Octuple_N indicates samples
frequency of nonsmokers/smokers are shown in C and D. The no
frequencies of oncogene mutations in these subgroups are sho
kinase gene; RET, ret proto-oncogene; MET, Met proto-oncogenWe also found two tumors with SNV mutations at the
exon 14 splicing site in the MET oncogene, which might
be related to MET exon 14 skipping (DEx14) (Fig. 2A).
Somatic mutations have been reported to cause MET
exon 14 skipping, which deletes binding sites for the Cbl
E3-ligase, thereby inducing prolonged activation of the
MET/MAPK pathway and ligand-dependent tumor
growth in vivo.40 Therefore, using the same method used
to screen for gene fusions (i.e., using a probe spanning
the MET exon 13–15 junction), we also checked for the
presence of the METDEx14 deletion mutation in all 271
tumors. Seven patients, including the two with mutations
at the splicing site, were found to express the DEx14
deletion mutant. We validated the exon skipping status
in six of seven tumor samples and determined whetherian patients with LUAD. (A) The OncoPlot summarizes the
left panel shows samples detected by Sequenom during the
d by whole-genome sequencing. Exon14_Skipping_Missense
splicing mutation nearest to exon 14. Samples not found to
onal frequency of detected oncogenes is shown in (B), except
. Sextuple_N indicates samples in which none of the tested
sine kinase 2 gene (ERBB2)/EGFR exon 20 insertion mutations
in which no known oncogenes were detected. The oncogene
nsmoker group is divided into two subgroups by sex, and the
wn in E and F. ALK, anaplastic lymphoma receptor tyrosine
e tyrosine kinase.
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level by using reverse-transcriptase PCR and Sanger
sequencing (Supplementary Fig. 6). Six METDEx14
events (2.2% of 271 cases) were largely mutually
exclusive with the other oncogene mutations identiﬁed
in our study (see Fig. 3A). Patient 292T was the only
tumor with an additional oncogenic KRAS mutation
(G12F) and showed partial exon skipping at METDEx14
(see Supplementary Fig. 6), which indicated that it might
have arisen from two independent oncogenic clones. A
cell line (NCIH596) that expresses METDEx14 was sen-
sitive to MET inhibition in vitro and in vivo,41 and data
from a few recent reports demonstrated the clinical ef-
ﬁcacy of crizotinib and cabozantinib in METDEx14 pa-
tients with LUAD.42,43 Taken together, these results
suggested that the METDEx14 mutation may occur in a
distinct subset of the population of patients with NSCLC
who may beneﬁt from treatment with approved MET
inhibitors such as crizotinib and cabozantinib.
In addition, we also found two tumors with oncogenic
BRAF V600E.44 We were able to validate these two
mutations by PCR and Sanger sequencing (see
Supplementary Fig. 5) and observe that the BRAF mu-
tations were mutually exclusive with the other driver
mutations. A few instances of patients with NSCLC
harboring the BRAF V600E mutation have been reported
to be responsive to BRAF inhibitors such as vemur-
afenib45 or dabrafenib.46 The NRAS Q61R mutation was
detected only in a tumor from patient 45T. The Inte-
grative Genomics Viewer plot of this mutation is shown
in Supplementary Figure 7.
Two tumor-suppressor genes (TP53 and SETD2)
were also mutated in our cohort. Three patients had
SETD2 mutations, with tumor 99T having two SETD2
mutations, 8 eight tumors having TP53 mutations, and
only tumor 124T having two TP53 mutations (Fig. 2A).
Except for SETD2 p.Q2298*, all the mutations have been
reported in the Catalogue of Somatic Mutations in Cancer
database (v64).
We further investigated the frequency of aforemen-
tioned recurrent oncogenic events (ERBB2 and EGFR in-
sertions, BRAF V600E) in 22 of the remaining 29
quintuple-negative cases. Insufﬁcient DNA remained for
such analysis for seven tumors. The remaining 22
quintuple-negative tumors were screened for mutations
by PCR and Sanger sequencing. Tumor 457T was positive
for the ERBB2 p. A775_G776insYVMA insertion, and tu-
mor 459T harbored a detectable BRAF V600E mutation.
Diversity of Oncogenic Mutations in LUAD
We comprehensively studied the prevalence of
oncogenic drivers by prescreening for well-established
drivers, together with analysis for novel oncogenic
events by WGS. In total, oncogenic mutations wereidentiﬁed in 229 tumor samples, and their prevalence is
shown in Figure 3A and Supplementary Table 8. We
demonstrated that 85% of patients with LUAD harbored
actionable oncogenic driver mutations, and among them,
nearly 87% had mutations that were treatable with U.S.
Food and Drug Administration–approved targeted ther-
apies (Fig. 3B). Notably, EGFR mutations were more
prevalent in nonsmokers and KRAS mutations were
more common in smokers (Fig. 3C and D). In summary,
more than 90% of nonsmoker patients with LUAD
(including both male and female patients) had single
oncogenic driver mutations, except for patient 292T,
who had METDEx14 and KRAS (G12F) mutations
(Fig. 3C, E, and F).
To compare the frequency of oncogenic driver genes
occurring between Asian and white patients with LUAD,
we also studied data from 172 white patients with
LUAD (Supplementary Table 9) from a publication by
TCGA13 in which DNA and RNA sequencing was per-
formed. Nearly 60% of the white patients with LUAD
were found to harbor one of the eight known oncogene
mutations (Supplementary Table 10), whereas the rate
was as high as 85% patients in the Asian population
from this study. These ﬁndings indicated that fewer
unknown oncogenes were present in the population of
Asian patients with LUAD (Fig. 4A), highlighting an
ethnic difference in LUAD. Signiﬁcantly, the mutation
frequency of EGFR was more than twofold higher in
Asians relative to that observed in white patients
(Fig. 4A). Because only one Asian patient with LUAD
harbored an NRAS mutation and none was reported in
white patients with LUAD, we did not include the NRAS
mutation in Fig. 4A.
Because age and smoking status were signiﬁcantly
different in the two populations (Supplementary
Fig. 8), we divided the samples into two groups
based on the median values of age and smoking status.
Using Fisher’s exact test and Monte Carlo simulation
to calculate p values, we found that the frequency of
oncogenic mutations did not have a signiﬁcant age
bias but was inﬂuenced by the smoking status.
Therefore, the patients were subdivided on the basis
of smoking status to compare oncogene mutational
frequencies in the two populations (Fig. 4B and C). In
the smoking cohort, nearly 70% of Asian patients with
LUAD had known oncogenic mutations compared with
only 53% of white patients. Moreover, oncogenic EGFR
mutations represented the most prevalent driver in
Asian smokers with LUAD. In contrast, KRAS muta-
tions were the primary oncogene mutated in white
smokers.
More detailed comparisons of mutational statuses
were performed for the EGFR and KRAS oncogenes in
samples of patients with LUAD. To fulﬁll statistical
Figure 4. Distribution of oncogene mutation frequencies in Asians compared with in whites. (A) Differing frequencies of
oncogenic mutations in Asian patients and white patients. p Values were calculated by Pearson’s chi-square test with the
simulated p value method, as shown in the top of the ﬁgure. Comparison of oncogene frequencies between the Asian and white
populations was also performed across the smoking group (B) and the nonsmoking group (C). Sextuple_N indicates that no
known oncogene was detected and that no recurrent erb-b2 receptor tyrosine kinase 2 gene (ERBB2)/EGFR exon 20 insertion
mutations were screened for in the samples. Octuple_N indicates samples in which no known oncogenes were detected. MET,
Met proto-oncogene tyrosine kinase; RET, ret proto-oncogene; ALK, anaplastic lymphoma receptor tyrosine kinase gene.
December 2016 Oncogenic Drivers in Asian LUAD 2137analysis requirements, we merged data from a previous
study16 (Supplementary Table 11), which contained 154
LUAD samples from white patients, with that of the
TCGA study. The KRAS mutational frequency in AsiansFigure 5. Distribution of mutation (Mut) types in the KRAS onc
white populations, with or without KRAS mutations. (B) Compar
mutations. p Values were calculated by Pearson’s chi-square t
KRAS mutation types. Type G12other indicates that the 12th am
or V. G13all indicates all mutations occurring at amino acid 13was signiﬁcantly lower than that in whites regardless of
smoking status (Fig. 5). The G12C mutation in KRAS,
which was detected in 50% of white patients with LUAD
with oncogenic KRAS mutations, was much less frequentogene. (A) Comparison between tumors from the Asian and
isons between Asian and white smokers, with or without KRAS
est with continuity correction. (C) The number of different
ino acid was changed to any amino acid other than A, C, D, S,
of KRAS. WT, wild type.
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KRAS mutations, including G12A and G13* (all mutations
at amino acid 13), were not identiﬁed in the Asian pa-
tients. After analyzing the consequences of these onco-
genic mutations on KRAS function with PolyPhen-2 and
SIFT software (see Supplementary Table 12), we found
that G13C, G12C, and G12V were predicted to cause the
greatest impact. These mutations were present with a
higher frequency in white patients with LUAD than in
Asian patients with LUAD (Fig. 5). Our ﬁndings sug-
gested that highly deleterious mutations in KRAS are
more frequent in whites than in Asians. L858R and exon
19 deletions are two dominant EGFR mutations in both
Asian and white patients with LUAD (Supplementary
Fig. 9B). When we correlated the oncogenic driver
prevalence with patient demographics, we found that
EGFR was more frequently mutated in female non-
smokers in both the Asian and white populations
(Supplementary Table 13), and no other gene was
correlated with the clinical parameters. Although we
found that KRAS mutations were more prevalent in
smokers, the difference was not signiﬁcant in our cohort.
No signiﬁcant differences were associated with the
presence of KRAS, EGFR, gene fusions, or other onco-
genes in terms of progression-free survival and overall
survival (Supplementary Fig. 10).Discussion
Asians, especially nonsmoking women, have a higher
incidence of LUAD.47 Asian women also have a higher
EGFR mutation rate than do patients of European
ancestry, leading to better response rates with EGFR
inhibitors.48 However, LUAD is relatively less studied in
Asians in terms of oncogenic drivers beyond the EGFR
and KRAS mutations.
The results from our study demonstrated that Asian
patients with LUAD harbor driver mutations similar to
those in white patients, in both the smoker and
nonsmoker subgroups. The EGFR mutations were found
to be the dominant driver in both Asian and white
nonsmoker patients, and they were the leading driver in
Asian smokers. However, KRAS mutations were the
leading driver of LUAD in white smokers. Our result
conﬁrms that EGFR testing should be performed for all
patients with LUAD, regardless of smoking status.
The data presented in this study show that EGFR,
KRAS, ERBB2, and BRAF mutations; ALK, ROS1, and RET
gene fusions; and MET exon 14 skipping are the major
drivers in LUAD in Asian patients, accounting for
approximately 70% of drivers in smokers and approx-
imately 90% of drivers in nonsmoker patients. Tumors
harboring EGFR mutations (mainly L858R and exon 19
deletions) can be treated by EGFR inhibitors such asgeﬁtinib and erlotinib. Similarly, targeted therapy is
available for patients with ALK fusions in the form of
the anaplastic lymphoma kinase inhibitors crizotinib
and ceritinib, and results from recent clinical trials with
ROS1 and ret proto-oncogene inhibitors in patients
with ROS1 and RET gene fusions have generated
promising data.49 Thus, our data suggest that more than
50% of smoker and 70% of nonsmoker patients with
LUAD can be treated by targeted tyrosine kinase in-
hibitors, which represent the highest rates of targeted
therapies among all common solid tumors. We would
like to point out that the results should be interpreted
with caution, especially when applying them to
advanced LAUD, because most of the cases in this study
were localized (mainly stage I).
In conclusion, by screening for known mutations and
performing WGS on tumor samples without known
driver mutations, we revealed a comprehensive land-
scape of oncogenic drivers in Asian patients with LUAD.
These ﬁndings should be helpful not only in developing
better molecular diagnostics strategies but also in
administering more effective targeted therapeutics.
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